Medicus Pharma Ltd. has announced updates on its clinical development program for a novel Doxorubicin Containing Microneedle Array (D-MNA) aimed at treating Basal Cell Carcinoma $(BCC)$ of the skin. The U.S. Food and Drug Administration (FDA) has accepted the company's Type C meeting request, with Medicus having submitted queries and anticipating a response by the end of Q3 2025. The SKNJCT-003 Phase 2 clinical study, currently being conducted across nine clinical sites in the United States, has randomized over 75% of the targeted 90 participants. The study began in August 2024, and an interim analysis in March 2025 indicated more than 60% clinical clearance, although these preliminary results may not reflect the final study outcomes. The investigational review board has increased the study's participant number to 90, and the company plans to expand trial sites in Europe. The purpose of the Type C meeting is to discuss D-MNA's product development and seek alignment on the clinical pathway, with the aim of fast-tracking the program. Results from the study are expected to be presented in the future.